White Paper · September 2026
Scientific Foundations for the Use of Arbaclofen in Autism Spectrum Disorder
A white paper prepared for discussion with the U.S. Food and Drug Administration, summarizing the mechanistic, nonclinical, and human pharmacodynamic evidence supporting the arbaclofen program in Autism Spectrum Disorder.
The full document is available as a copyrighted PDF. Please tell us who you are and the download will begin.
Request the white paper
11 pages, including the executive summary, twelve sections, and 23 references.
Every page is watermarked. © 2026 Allos Pharma Inc. All rights reserved. Confidential, not for redistribution.
Arbaclofen is an investigational drug and has not been approved by the FDA or any regulatory authority.
Partnership
Let's bring arbaclofen to the patients and families who need it.
Partner with Allos to accelerate the first disease-modifying treatment for ASD and Fragile X Syndrome.